ELBCC Modern Pathology Anne Vincent-Salomon Patrick WB Derksen COST #lobular breast cancer #ILC is NOT a rare subtype (=15% of all breast cancers!). Suboptimal inter-pathologist concordance has been repeatedly reported. See our ELBCC efforts to harmonise pathological diagnostic guidelines! Please apply in clinical practice and trials OncoAlert

🧬New study on germline CDH1 variants shows lifetime cancer risks: 🧬Gastric cancer: 7% to 10% by age 80 🧬Breast cancer (female carriers): 37% ▶️These findings indicate a lower gastric cancer risk and similar breast cancer risk compared to previous estimates. Important for

Let's together change how the UK treats #LobularBreastCancer and get the most effective treatments for #Lobular patients. Complete our survey if you have been diagnosed with #LCIS or #ILC buff.ly/4eQWvXv #TreatmentGuidelines #BreastCancer

Ένα βίντεο τρυφερό & πανέμορφο - Ύμνος στην δική του Ελλάδα, το Μεσολόγγι |Νίκος Αλιάγας eirinika.gr eirinika.gr/article/275024… via Ειρήνη Νικολοπούλου

Over 1,900 downloads in less than a week for our educational chapter on systemic therapy in #breastcancer. Thank you! Easy access here: ascopubs.org/doi/10.1200/ED… #teamwork #bcsm William Gradishar, MD Rebecca Shatsky, MD Hemali Batra-Sharma, MD UC San Diego Health Moores Cancer Center ASCO Journal of Clinical Oncology Dana-Farber’s Breast Oncology Center

In the culture of modern science we are taught to look up to those who didn't give up when things were not working & persisted & tried again & again. which is of course fine but we need to look up to, at least as much, those who realised things were not working & changed projects

So important notion and caution.

HER2: a remarkable story of precision oncology. Check this wonderful Nature review on targeting HER2 beyond breast. 👉Important to remember: now that we have an agnostic anti-HER2 drug approved (T-DXd), every adv cancer patient should get HER2 testing! nature.com/articles/s4157…

The fascinating Rosen's triad! 👌

Community-informed collaborative research agenda, with the goal of improving management and personalizing treatment for patients with ILC. #lobular

Long-term outcomes by lobular vs ductal histology in four NSABP adjuvant BC trials 📌Patientts with ILC were older, had larger and more frequent ER-positive tumors, and more positive LN 📌Compared to NST (ductal) pts, those with ILC had a higher risk of late recurrence and

Congrats to the team on our study showing long-term outcomes by lobular versus ductal histology in four large NSABP adjuvant breast cancer trials (B-22, B-25, B-28, B-30). Patients with ILC have elevated risk of late recurrence and death. academic.oup.com/jnci/article-a… UPMC Hillman Cancer Center

Hybrid conferences should be the norm — optimize them so everyone benefits nature.com/articles/d4158…

📌 Clinical management of oligometastatic cancer: Applying multidisciplinary tumor board recommendations in practice doi.org/10.1016/j.ctro… Matthias Guckenberger 👉🏻 generally high adherence to and implementation of MDT-recommended algorithms for OMD patients. 👉🏻 this study underscores the

Improving the predictive power of mouse models go.nature.com/3yNEUze

Nice read about the interplay of extracellular matrix #ECM remodeling, tumor microenvironment #TME, and targeting ECM remodeling in clinical settings.

Now Online Mechanisms of assembly and remodelling of the extracellular matrix dlvr.it/TCjr0l

Hot off the press! "Mechanisms of assembly and remodelling of the extracellular matrix" is now out in Nature Reviews Molecular Cell Biology doi.org/10.1038/s41580… It is a privilege to have been asked to review the current state of #ECM research and discuss exciting emerging research avenues, a 🧵:

Discover the exciting programme of sessions confirmed so far for the #EACR2025 Congress! Expect a range of Plenary sessions, Symposia, Meet the Expert panels and Educational Sessions: 2025.eacr.org/programme

We've picked the most interesting recent cancer research papers in our newest edition of Highlights in Cancer Research 💡 magazine.eacr.org/highlights-in-…